Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Pediatric access widens for rare immune disease therapies

Pediatric access widens for rare immune disease therapies

Rule Changes

FDA broadens ADMA's ASCENIV antibody therapy to children as young as two

May 4th, 2026: FDA approves ASCENIV for children aged 2 and older

Overview

For seven years, an immune therapy made from antibody-rich human plasma was available only to teenagers and adults. On May 4, 2026, the FDA extended ADMA's ASCENIV to children as young as two, ending the reliance on off-label or alternatives.

The decision is a quiet milestone: pediatric label expansions for rare-disease therapies. These expansions occur when therapies meet post-marketing study commitments tied to their original approvals. For families managing primary humoral immunodeficiency (the inability to produce antibodies to fight common infections), the therapy shifts from something doctors could only justify carefully to one with regulatory backing for routine prescribing.

Why it matters

Young children with rare antibody deficiencies now have a specialized immune therapy approved for their age group, removing a longstanding gap in pediatric care.

Questions about this story

No questions yet — be the first to ask.

Play on this story Voices Debate Predict

Key Indicators

Age 2
New minimum age
Lowered from 12, enabling earlier intervention for immune-compromised children.
1 in 500
U.S. primary immunodeficiency rate
Estimated prevalence of inherited immune disorders among Americans.
$363M
ASCENIV 2025 revenue
ADMA's specialty IVIG product grew 51% year-over-year before the pediatric label.
2019
Original approval
ASCENIV first approved for patients 12 and older with primary humoral immunodeficiency.
Lifelong
Typical treatment duration
Most patients with primary humoral immunodeficiency need antibody replacement for life.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 4 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Timeline Five events from this story — drag them oldest to newest. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Adam Grossman
Adam Grossman
Leading commercial expansion of ASCENIV into pediatrics
 Kaitlin Kestenberg
Kaitlin Kestenberg
Oversaw pediatric post-marketing study and sBLA filing

Organizations Involved

ADMA Biologics, Inc.
ADMA Biologics, Inc.
Biopharmaceutical Company
Manufacturer of ASCENIV; commercial beneficiary of label expansion

A vertically integrated specialty biologics company that collects plasma, manufactures immune globulin therapies, and markets them to immune-compromised patients.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal Agency
Approved supplemental application expanding ASCENIV's pediatric indication

The federal agency that regulates biologic drugs, sets pediatric study requirements for new approvals, and reviews supplemental applications to expand product labels.

Timeline

April 2019 May 2026

6 events Latest: May 4th, 2026 · 1 month ago
Tap a bar to jump to that date

  1. FDA approves ASCENIV for children aged 2 and older

    Latest Regulatory

    The FDA approves the supplemental application, expanding ASCENIV to pediatric patients aged 2 to 11 and satisfying ADMA's pediatric post-marketing commitment.

  2. ADMA files pediatric sBLA

    Regulatory

    ADMA submits a supplemental biologics license application requesting expansion of the ASCENIV label to patients two years and older.

  3. Pediatric study database locked

    Clinical

    All pediatric patients enrolled in the post-marketing study complete their treatment schedules, and ADMA closes the database in preparation for the supplemental filing.

  4. FDA clears extended room-temperature storage

    Regulatory

    Storage flexibility for ASCENIV and BIVIGAM is broadened, simplifying logistics for home infusion and pediatric clinics that lack continuous cold-chain capacity.

  5. ASCENIV begins commercial sales

    Commercial

    ADMA Biologics names BioCareSD its primary distributor and reports first commercial sales of ASCENIV to specialty pharmacies and infusion providers.

  6. FDA approves ASCENIV for ages 12 and older

    Regulatory

    The FDA grants original approval for ASCENIV to treat primary humoral immunodeficiency in adults and adolescents, with a post-marketing commitment to study the drug in younger children.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

December 2003

Pediatric Research Equity Act passed (2003)

Congress made permanent the FDA's authority to require pediatric studies for new drugs and biologics likely to be used in children. Manufacturers could defer studies to a post-approval commitment, but the obligation became enforceable.

Then

New drug approvals began routinely carrying pediatric study requirements, often as post-marketing commitments tied to specific deadlines.

Now

Hundreds of products have since had labels updated to add pediatric data, gradually closing gaps where children received off-label prescribing of adult drugs.

Why this matters now

ASCENIV's 2026 pediatric expansion is a direct product of this regulatory framework: the 2019 approval included a pediatric study commitment that this supplemental application now fulfills.

May 2018

BIVIGAM pediatric approval (2018)

ADMA's other intravenous immune globulin product, BIVIGAM, received FDA approval that already included pediatric patients aged 2 and older—a different regulatory path than ASCENIV's adolescent-first approval one year later.

Then

ADMA had a pediatric-eligible IVIG in its portfolio while ASCENIV remained restricted to adolescents and adults.

Now

The split labels created a portfolio gap that the 2026 ASCENIV expansion now closes, allowing ADMA to position both products for pediatric immunologists.

Why this matters now

Shows that pediatric label coverage is a competitive feature within ADMA's own product line, not just across rival manufacturers.

April 2019

Original ASCENIV approval (April 2019)

The FDA approved ASCENIV for primary humoral immunodeficiency in adults and adolescents based on a pivotal study of 59 patients treated for 12 months, with a requirement to subsequently study children aged 2 to 11.

Then

Commercial launch followed in late 2019, with ASCENIV positioned as a specialty IVIG differentiated by RSV-antibody-enriched plasma.

Now

ASCENIV grew into ADMA's top revenue driver, reaching $363 million in 2025 sales—creating commercial incentive to complete the pediatric study and expand the addressable patient population.

Why this matters now

The current event is the closing chapter of the regulatory commitment opened seven years ago; it also unlocks the pediatric portion of an already fast-growing franchise.

Sources

(7)
+1
GlobeNewswire Conexiant Pediatrics GuruFocus U.S. Food and Drug Administration Pharmacy Times Immune Deficiency Foundation GlobeNewswire